Month: May 2021

MONTREAL, May 14, 2021 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its first quarter ended March 31, 2021. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified. Q1 2021 Highlights FinancialsRevenues were $46,069, an increase of $230 or 1% over prior year. Gross margin generated of $20,580 or 45% compared to $19,860 or 43% in prior year. Adjusted EBITDA1 was $5,580, an increase of $2,383 or 75% over prior year. Interest income generated of $1,998 a decrease of $2,651 or 57% over prior year. Net income was $3,558 compared to net loss of $9,477 in prior year. Cash inflow from operations was $17,207...

TORONTO, May 14, 2021 (GLOBE NEWSWIRE) — Arena Minerals Inc. (“Arena” or the “Company”) (TSX-V: AN) is pleased to announce completion of the sale of the Pampa Paciencia epithermal gold property (the “Property”), located in the Atacama region of northern Chile, to Astra Exploration Ltd (“Astra”), a private mineral exploration company. In consideration for Arena’s 80% ownership of the Property the Company has received 5.82 million of shares of Astra, representing 40% of the issued and outstanding shares of Astra with a deemed value of $1.6 million. Astra is a newly formed private mineral exploration company led by a proven management team with previous exploration success in discovering epithermal gold deposits. Astra intends to initiate a drill program on the Property and complete a going public transaction...

Image 1Image 1Image 2Image 2Image 3Image 3Image 4Image 4Image 5Image 5Image 6Image 6Image 7Image 7New Letter to Shareholders Provides Comprehensive Discussion of the Transaction Rationale and the Immediate, Certain and Compelling $19.50 Per Paired Share Cash Value Addresses Tarsadia’s Misleading and Flawed Arguments Urges Shareholders Vote “FOR” the Transaction on the WHITE Company Proxy Card in Vote Set for June 8, 2021 CHARLOTTE, N.C., May 14, 2021 (GLOBE NEWSWIRE) — Extended Stay America, Inc. (“ESA”) and its paired-share REIT, ESH Hospitality, Inc. (“ESH” and, together with ESA, “Extended Stay” or the “Company”) (NASDAQ: STAY) today sent a new letter to shareholders detailing the strategic and economic factors...

14 May 2021 Notice of Q1 2021 IFRS Results   Acron (LSE: AKRN) will release its IFRS financial results for Q1 2021 on Monday, 17 May 2021 at 11.00 am (Moscow time).Media contacts: Sergey Dorofeev Anastasiya Gromova Tatiana Smirnova Public Relations Phone: +7 (495) 777-08-65 (ext. 5196) Investor contacts: Ilya Popov Sergey Smirnov Investor Relations Phone: +7 (495) 745-77-45 (ext. 5252)     Background Information Acron Group is a leading vertically integrated mineral fertiliser producer in Russia and globally, with chemical production facilities in Veliky Novgorod (Acron) and Smolensk region (Dorogobuzh). The Group owns and operates a phosphate mine in Murmansk region (North-Western Phosphorous Company, NWPC) and is implementing a potash development project in Perm Krai (Verkhnekamsk Potash Company, VPC). It owns transportation and logistics...

Figure 1Zone of massive visual Cassiterite in BGH030 – 10.6 metres @ 4.85% SnFigure 2Mpama South Long section and Potential New High-grade PayshootFigure 3Mpama South Interpretation Section 9884840Figure 4Mpama South Interpretation Section 9884750Figure 5Mpama South Interpretation Section 9884650Figure 6High Priority Targets Following the Mpama North BlueprintGRAND BAIE, Mauritius, May 14, 2021 (GLOBE NEWSWIRE) — Alphamin Resources Corp. (AFM:TSXV, APH:JSE AltX, “Alphamin” or the “Company”), a producer of 4% of the world’s mined tin from its high-grade operation in the Democratic Republic of Congo, is pleased to provide initial assay results and an exploration update on its Mpama South Exploration Drilling programme. HIGHLIGHTSHigh-grade...

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 14, 2021 (GLOBE NEWSWIRE) — TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced financial results for the first quarter ended March 31, 2021 and provided a business update. “The first quarter of 2021 is marked by continual progress in our lead programs, TLC599 and TLC590, as well as the global commercialization of Ampholipad, for which we look forward to announcing the details when they are finalized,” commented George Yeh, President of TLC. “We are happy to announce that we have once again made the top 5% ranking in Taiwan’s corporate governance evaluation. Being the only biotech company to have achieved this honor seven years in a row, we think this is an incredible...

TORONTO, May 14, 2021 (GLOBE NEWSWIRE) — Victoria Gold Corp. (TSX-VGCX) (“Victoria” or the “Company”) is pleased to announce first quarter 2021 summary financial and operating results. The Company uses certain non-IFRS performance measures throughout this news release; please refer to the “Non-IFRS Performance Measures” section of this news release for more information. All amounts are in Canadian dollars unless otherwise indicated. This release should be read in conjunction with the Company’s Financial Statements and Management’s Discussion and Analysis (“MD&A”) for the three months ended March 31, 2021 and 2020, available on the Company’s website or on SEDAR. Mr. John McConnell, President and CEO commented, “As expected with seasonal ore placement on the heap leach pad, ore stacking and gold production grows quarter over...

FDA Review of NDA for Oral Sulopenem Continues; Current Prescription Drug User Fee Act (PDUFA) date of July 25, 2021 Cash Runway into First Half of 2023 Company to host conference call today at 8:30am ET DUBLIN, Ireland and CHICAGO, May 14, 2021 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the first quarter ended March 31, 2021. “We continue to prepare for a U.S. Food and Drug Administration (FDA) advisory committee meeting and look forward to clarity from the FDA on timing. In the meantime, the FDA continues its review of our new drug application (NDA) for oral sulopenem for...

Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, May 14, 2021 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the first quarter ended March 31, 2021 and provided an update on recent corporate developments. “The start of 2021 has been marked by substantial progress across our portfolio of targeted nucleic cancer drugs which included both presented and published data in support of our DNAbilize platform,” stated Peter Nielsen, President and Chief Executive Officer of Bio-Path Holdings. “We recently announced the successful completion of the safety run-in of Stage 2 of the Phase 2 clinical study of prexigebersen...